# Apogee Therapeutics Inc. (APGE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $135.07, market value $10.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Apogee Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 8.5×**. The shares trade at 8.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Growth
- **EPS growth (1 yr): -27.9%**. Earnings per share fell 27.9%.

## Financial health
- **Current ratio: 26.57** (quick 26.57). Current assets cover the next year's liabilities 26.57 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Apogee Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 256.8%** (YTD 78.9%, 3-mo 60.4%). The shares are up 256.8% over twelve months including dividends.
- **From 52-week high: -0.0%** (281.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 79**. An RSI of 79 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.93** (volatility 70%). Beta of 0.93 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=APGE · Page: https://foliofundamentals.com/stocks/apge

Not investment advice.